Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Viking Therapeutics stock plunged Thursday on a relatively light earnings report that included mostly incremental updates for ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. Many investors ...

VKTX stock opened at $30.48 on Thursday. Viking Therapeutics has a fifty-two week low of $28.64 and a fifty-two week high of $99.41. The business’s 50-day moving average is $37.97 and its two ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares.

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price ...

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss ...